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ABSTRACT 
Glucocorticosteroids are widely used in the treatment of asthma and chronic obstructive 
pulmonary disease (COPD). However, there are growing concerns about the side effect 
profile of this class of drug, particularly an increased risk of pneumonia. Over the last two 
decades there have been many attempts to find drugs to allow a reduction of 
glucocorticosteroids, including xanthines such as theophylline. Use of xanthines has been 
shown to lead to a reduction in the requirement for glucocorticosteroids, although xanthines 
also have a narrow therapeutic window limiting their wider use. Doxofylline is another 
xanthine that has been shown to be of clinical benefit in patients with asthma or COPD, but to 
have a wider therapeutic window than theophylline. In the present study we have 
demonstrated that doxofylline produces a clear steroid sparing effect in both an allergic and a 
non-allergic model of lung inflammation. Thus, we have shown that concomitant treatment 
with a low dose of doxofylline and a low dose of the glucocorticosteroid dexamethasone (that 
alone had no effect) significantly reduced both allergen-induced eosinophil infiltration into 
the lungs of allergic mice, and lipopolysaccharide (LPS)-induced neutrophil infiltration into 
the lung, equivalent to a higher dose of each drug. Our results suggest that doxofylline 
demonstrates significant anti-inflammatory activity in the lung which can result in significant 
steroid sparing activity. 
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INTRODUCTION  
Glucocorticosteroids are widely used drugs in the treatment of patients with asthma or 
COPD[1]. However, this class of drug are known to exhibit a wide variety of side effects 
which has prompted considerable efforts to find pharmacological approaches to try and 
reduce the dose of glucocorticosteroids without compromising efficacy. Thus, recent  clinical 
data has shown that treatment with anti-IL5 can reduce glucocorticosteroid usage in patients 
with severe asthma [2]  and the addition of a long acting B2 agonist to a low dose of an 
inhaled glucocorticosteroid has been demonstrated to produce an improved clinical outcome 
to doubling the dose of the inhaled glucocorticosteroid suggested as the scientific justification 
for the success of combination inhalers [3]. Xanthines are drugs widely used in the treatment 
of respiratory diseases and exhibit both bronchodilator and anti-inflammatory actions [4]. 
However, xanthines such as theophylline have a very narrow therapeutic window and elicit a 
wide range of dose-dependent side effects [5, 6]. Furthermore, xanthines must be used with 
caution when co-prescribed with other drugs as there are many reported drug/drug 
interactions that can also lead to adverse effects. This has led to the search for newer drugs 
with an improved safety profile, including enprofylline, bamifylline and doxofylline which 
have been referred to as “novofyllines” [7]. Clinical data has suggested that doxofylline has a 
wider therapeutic window than theophylline, and exhibits less cardiovascular and 
gastrointestinal side effects  (Reviewed in [7]).  Recent experimental work has suggested that 
this improved therapeutic window may be due to doxofylline lacking either significant 
adenosine receptor antagonism or inhibition of phosphodiesterase enzymes (PDEs), such as 
PDE3 expressed in the cardiovascular system [8], mechanisms that are thought to contribute 
to the side effect profile of theophylline [9]. 
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We, and others, have demonstrated that doxofylline has significant anti-inflammatory actions 
[10, 11], including the ability of this drug to reduce leukocyte recruitment into the airways 
[12].  However, whilst there have been a number of studies reporting the ability of 
theophylline to have a steroid sparing action [13, 14], and indeed to have complimentary anti-
inflammatory activity to corticosteroids, there is only limited data with doxofylline. Given the 
recent concern about the increased risk of pneumonia in patients with asthma [15] or COPD 
[16], regularly prescribed corticosteroids, and in the recognition that this class of drugs have 
only limited benefit in many patients with COPD, there have been many new 
pharmacological approaches to reduce the need for corticosteroids in patients with respiratory 
diseases. Since doxofylline has been demonstrated to have anti-inflammatory activity [12] 
and to show significant clinical benefit in both adults and children with asthma or COPD, we 
have investigated whether doxofylline can exhibit corticosteroid sparing activity in murine 
models of non-allergic (LPS) and allergen-induced leukocyte infiltration into the lung.  We 
have utilised bacterial LPS as the model for non allergic leukocyte infiltration as this is 
known to be a good stimulus to induce neutrophil recruitment into the lung, both 
experimentally [17, 18]  and clinically [19-21], and we have used a well established model of 
allergic inflammation in the airways to investigate whether doxofylline can have 
corticosteroid sparing activity against allergen-induced eosinophil infiltration into the lungs 
of mice. 
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METHODS 
Animals 
Male and female BALB/c mice, 6 to 8 weeks old, were used in this study (Envigo, UK). 
Experiments were approved by the Home Office under The Animals (Scientific Procedures) 
Act (1986) and local approval from the Ethics Committee of King’s College London. Our 
research was carried out adhering to the recommendations of the ARRIVE guidelines for 
using animals in research [22] 
 
Non allergic Inflammation 
Male Balb/c mice received 10 µg of LPS (E. Coli, Sigma, UK) intranasally under light 
anaesthesia with isoflurane.  
Allergic Inflammation 
Female Balb/c mice were immunized intra-peritoneally with 30 µg of chicken egg albumin 
(OVA type V; Sigma, UK) absorbed to a saturated solution of aluminium hydroxide (2.5 
mg/ml; Sanofi, Brazil) [23, 24] [23, 24] [23, 24] . Controls received aluminium hydroxide 
only. Five and 10 days later (day 5 and 10) the injection of OVA was repeated. On day 14 to 
16, all animals were challenged with an aerosolised solution of OVA (3%) for 25 minutes, 
once daily.  
Drug treatment 
Doxofylline (Eurodrug Laboratories, The Hague, The Netherlands) was administered 
intraperitoneally at 0.1, or 1mg/kg -24, -1 before, and 6h after intra-nasal instillation of 10µg 
of LPS or aerosol challenge with OVA. Dexamethasone (Sigma, UK) was injected 
intraperitoneally at 0.1, or 1 mg/kg -24h and 10 minutes before intra-nasal instillation of 
10µg of LPS or aerosol challenge with OVA. Montelukast Sodium (Pharmacopeia reference 
Standard) was injected intraperitoneally at 0.1 or 0.3 mg/kg -24h and 10 minutes before 
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aerosol challenge with OVA. Control mice were treated with saline only. In some 
experiments we administered a low dose of doxofylline (0.1 mg/kg) or montelukast (0.1 
mg/kg) with a low dose of dexamethasone (0.1 mg/kg). 
 
Bronchoalveolar lavage  
Twenty-four hours after LPS instillation, or the last OVA challenge in allergic animals, mice 
were euthanized with an overdose of urethane (25% solution i.p.; Sigma Chemical Co.) and a 
cannula was inserted into the exposed trachea and three 0.5 ml aliquots of saline were 
injected into the lungs. From the BAL fluid, an aliquot (50 µl) was added to 50 µl of 
haemolysis solution (Turk’s solution, Fluka, UK). The total number of cells in the lavage was 
counted with an improved Neubauer haemocytometer. For differential cell counts, cytospin 
preparations were prepared from aliquots of BAL fluid (100 µL) centrifuged at 1000 rpm for 
1 min using a Shandon Cytospin 2 (Shandon Southern Instruments, Sewickley, PA, USA) at 
room temperature. Cells were stained with Diff Quick (DADE Behring, Germany) and a total 
of 100 cells were counted to determine the proportion of neutrophils, eosinophils and 
monocytes using standard morphological criteria. 
Statistical analysis 
Data were analyzed using ANOVA followed where appropriate by a post hoc test 
(Bonferroni; SPSS version 20) and differences between mean values considered significant if 
p < 0.05.  
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RESULTS 
LPS-induced neutrophil migration into the lung lumen 
The total number of cells quantified in BAL fluid obtained from LPS- treated mice (LPS) 24 
h following intra-nasal instillation was significantly higher compared to saline-treated mice 
(LPS: 196.8 ± 10.3 x 104 cells/ml, n=5 versus Saline: 27.2 ± 3.2 x 104 cells/ml; n=5; p < 
0.05;). This was reflected by a significantly greater number of neutrophils recruited to the 
airways in LPS-treated mice (170.4 ± 8.7 x 104 cells/ml) versus saline-treated mice (0.2 + 0.1 
x 104 cells/ml; δp < 0.0001, Figure 1A). The intensity of the inflammatory response was 
significantly reduced in animals treated with 1mg/Kg of dexamethasone (p<0.0001, n=5 and 
1mg/kg of doxofylline (p<0.01, n=6), but not with the lower doses of either drug (0.1mg/kg). 
However, the combination of 0.1 mg/kg of dexamethasone and 0.1 mg/kg doxofylline, 
concentrations that alone did not significantly alter the response to LPS, did significantly 
inhibit the migration of neutrophils to the lung in response to 10 µg of LPS (Fig. 1 B, 
p<0.0001, n=5).  
OVA-induced eosinophil migration to the lung lumen 
The total number of cells quantified in BAL fluid obtained from OVA-sensitized mice 
(OVA) 24 h following the last OVA challenge was significantly higher compared to sham-
immunized mice (OVA: 33.5 ± 3.5 x 104 cells/ml, n=10 versus Saline: 11.8 ± 1 x 104 
cells/ml; n=10, p<0.001). This was reflected by a significantly greater number of eosinophils 
recruited to the airways in OVA-sensitized mice (17.4 ± 2.9 x 104 cells/ml αp < 0.001, Figure 
2A). The intensity of the inflammatory response was significantly reduced in animals treated 
with 1mg/kg, but not with 0.1 mg/kg of dexamethasone (p<0.01, n=5), while with 1mg/kg of 
doxofylline again significantly reduced the inflammatory response (P<0.01, n=5). However, 
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treatment with Montelukast (0.1 or 0.3 mg/kg) or doxofylline (0.1 mg/kg) alone did not 
significantly alter allergen-induced eosinophil infiltration (Figure 1). Nonetheless, the 
combination of 0.1 mg/kg of dexamethasone and 0.1 mg/kg doxofylline significantly 
inhibited the migration of eosinophils into the lung in response to OVA (Fig. 2 B, p<0.0001, 
n=6). In contrast the combination of 0.1 mg/kg of dexamethasone and 0.1 mg/kg of 
montelukast did not significantly alter the response to OVA (Fig. 2 B, n=5).  
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DISCUSSION  
We report here that doxofylline, a xanthine drug that has been used as a treatment for 
respiratory diseases for more than 30 years [7], is able to exhibit corticosteroid sparing 
activity in two murine models of lung inflammation. We have demonstrated that doxofylline 
produced a dose dependent inhibition of both LPS-induced lung neutrophilia in healthy 
animals as we have previously reported [12]  and we have also demonstrated that this drug is 
able to inhibit allergen-induced eosinophil infiltration into the lungs in allergic mice. These 
results extend previous work demonstrating that doxofylline has anti-inflammatory activity of 
relevance to lung diseases such as asthma and COPD [12, 25, 26]. We have also 
demonstrated that the corticosteroid dexamethasone was able to inhibit both of these 
inflammatory insults as was to be expected from the wealth of data describing the anti-
inflammatory effect of this class of drugs. However, the combination of doxofylline with 
dexamethasone at doses that themselves did not induce any significant reduction in the 
inflammation induced by LPS or allergen produced highly significant reductions in leukocyte 
infiltration into the lung in both models. Indeed the anti-inflammatory effect of the low dose 
dexamethasone in the presence of a low dose of doxofylline was equivalent to around a 10 
times higher dose of dexamethasone administered alone. Clearly these results support the use 
of doxofylline as another drug able to reduce the need for corticosteroids, an observation that 
has also been recently observed in the clinic  [27]. Our work lends further support to the 
considerable data in the literature showing that other xanthines also have corticosteroid 
sparing activity [14, 28].  
Theophylline has been suggested to act co-operatively with corticosteroids by virtue of being 
able to interact with certain HDAC enzymes and thus enhancing the effect of corticosteroids 
on gene transcription in inflammatory cells, reducing the synthesis of pro-inflammatory 
mediators [13]. However, in previous work we found no evidence for doxofylline sharing this 
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effect with theophylline on any of the known HDAC enzymes [8] suggesting that the 
observed corticosteroid sparing effect of doxofylline in the present work is unlikely to be via 
an HDAC mediated mechanism. Furthermore, whilst xanthines are sometimes classified as 
non selective PDE inhibitors, and that particularly inhibition of PDE4 is known to be 
associated with anti-inflammatory activity, our previous work has suggested this is also not a 
property exhibited by doxofylline [8]. Thus, the precise mechanism of action of doxofylline 
to explain this corticosteroid sparing effect remains unknown. Nonetheless, we believe our 
observations are of considerable interest as they provide a good scientific rationale to further 
investigate doxofylline as a corticosteroid sparing agent in the clinic given it is a safe, orally 
active and effective drug for the treatment of asthma and COPD (6). Indeed a recent clinical 
study has suggested a corticosteroid sparing effect of doxofylline [29] which is supported by 
recent pharmacoeconomic data from Italy that in patients prescribed doxofylline for the 
treatment of their respiratory disease, there is less use of corticosteroids than in patients 
prescribed theophylline [30].  
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 Legend of the figures 
Figure 1. (A) Effect of dexamethasone or doxofylline on LPS-induced neutrophil migration 
to the lung. (B) Effect of the combination of dexamethasone/doxofylline on LPS-induced 
neutrophil migration to the lung. Bronchoalveolar lavage was collected 24 h post saline 
instillation (Saline) or instillation of 10 µg of LPS i.n. (LPS). Mice were treated with 
doxofylline (0.1 or 1mg/Kg i.p.), dexamethasone (0.1 or 1mg/Kg i.p.) or 
dexamethasone/doxofylline (0.1/0.1 mg/kg i.p.) -24, -1 and 6 hours after instillation with 
LPS. Vertical lines represent MEAN + SEM of 5-6 mice/ group. δp<0.0001 vs saline group, 
***p<0.00001 vs LPS group, *p< 0.001 vs LPS group,  ****p<0.00001 vs LPS group. One 
way ANOVA followed by Dunnett Post Hoc. 
 
Figure 2. (A) Effect of dexamethasone, doxofylline or montelukast on OVA-induced 
eosinophil migration into the lung.  (B) effect of the combination dexamethasone/doxofylline 
and doxofylline/montelukast on OVA-induced eosinophils migration to the lung. 
Broncoalveolar lavage was collected 24 h post aerosol challenge with OVA (OVA). Mice 
were treated with doxofylline (0.1 or 1mg/Kg i.p.), dexamethasone (0.1 or 1mg/Kg i.p.), 
montelukast (0.1 or 0.3 mg/kg i.p.), dexamethasone/doxofylline (0.1/0.1 mg/kg i.p.) or 
dexamethasone/montelukast (0.1/0.1 mg/kg i.p.)  -24, -1 and 6 hours after challenge with 
Ovalbumin. Vertical lines represent MEAN + SEM of 6-11 mice (OVA 
experiment).αp<0.001 vs sham group, *p<0.05 vs OVA group,, ***p<0.0001 vs OVA group. 
One way ANOVA followed by Dunnett Post Hoc. 
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